A first-in-human pilot trial suggests umbilical cord–derived mesenchymal stem cell eye drops may safely improve symptoms and ...
MSC-derived extracellular vesicles provide a novel cell-free nanotherapeutic strategy for hepatorenal syndrome and reveal a ...
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication. RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers ...
BioCardia, Inc. announced the completion of enrollment and dosing in the low dose cohort of its Phase I/II CardiALLO™ trial, which aims to treat patients with ischemic heart failure of reduced ...
Figure 1: Immunomodulatory effects of simulated MSCs. MSCs utilize different molecular mechanisms to suppress (in most cases) or activate immune cells. Orange arrows: inhibition; Green arrows: ...
The promise of mesenchymal stem cells (MSCs) to heal heart disease could be around the corner thanks to a new delivery method tested by regenerative medicine company Cynata Therapeutics Ltd.
Vietnam Investment Review on MSN
FDA Establishes First MSC Quality Control Protocol
TIANJIN, China, Jan. 26, 2026 /PRNewswire/ -- In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control standard for Mesenchymal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results